MNOV
MaterialsMedicinova Inc
Live · NASDAQ · May 9, Close
What's Moving MNOV Today?
No stock-specific AI insight has been generated for MNOV yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
MNOV News
20 articles- New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationGlobeNewswire Inc.·Apr 27, 2026
- Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst callsYahoo Finance·Mar 23, 2026
- MediciNova to Participate at the 38th Annual ROTH ConferenceYahoo Finance·Mar 16, 2026
- MediciNova: Q4 Earnings SnapshotYahoo Finance·Feb 20, 2026
- Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·Feb 19, 2026
- MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsYahoo Finance·Jan 29, 2026
- ATA Creativity Global Among 3 Promising Penny StocksYahoo Finance·Jan 20, 2026
- 2026 New Year’s Greetings from the CEOYahoo Finance·Jan 6, 2026
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyYahoo Finance·Dec 18, 2025
- Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsightYahoo Finance·Dec 9, 2025
- MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDYahoo Finance·Dec 8, 2025
- Message from the CEO to MediciNova ShareholdersYahoo Finance·Dec 1, 2025
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory AdvisorYahoo Finance·Nov 18, 2025
- MediciNova: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough AwardsYahoo Finance·Nov 6, 2025
- MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Yahoo Finance·Nov 4, 2025
- 3 Penny Stocks With Market Caps Over $80M To ConsiderYahoo Finance·Nov 3, 2025
- MediciNova compounds demonstrate novel therapeutic approach for AtherosclerosisYahoo Finance·Nov 1, 2025
- MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed PublicationYahoo Finance·Oct 30, 2025
- MediciNova to Present at the LD Micro Main Event XIX Investor ConferenceYahoo Finance·Oct 6, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.